MedTrace Logo

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis

NCT03943576 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-06-06

No results posted yet for this study

Summary

The aim of the investigators study was to investigate the safety and efficacy of allogeneic ADSCs for the clinical treatment of knee osteoarthritis.

Conditions

Interventions

DRUG

GXCPC1

The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)

DEVICE

HA

Hya Joint Plus synovial fluid supplement 3mL

Sponsors & Collaborators

  • Gwo Xi Stem Cell Applied Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Cheng-FONG Chen · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-04-27
Completion
2023-03-22

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03943576 on ClinicalTrials.gov